Medical Xpress· Medical Xpress - Cancer·· 19 hours agoPickScore58
Combination therapy reveals potential vulnerability in aggressive osteosarcoma
In brief
A St. Jude Children's Research Hospital team found that combining EP300 degradation with AKT inhibition produced a synergistic effect in patient-derived mouse xenograft models, slowing tumor growth and prolonging survival. Most osteosarcoma samples sensitive to EP300 degradation carried AKT pathway-activating mutations, and sensitive tumors had a lower overall protein synthesis rate than resistant tumors; these mutations may serve as sensitivity biomarkers for the combination.
Why it matters
Links AKT pathway-activating mutations to EP300 degradation sensitivity in a subset of osteosarcomas, supporting biomarker selection for combination therapy.
Source: Medical Xpress · medicalxpress.com